Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Alekseenko, Irina V ^a,b   Snezhkov, Eugene V ^a   Chernov, Igor P ^a   Pleshkan, Victor V ^a,b   Potapov, Victor K ^a   Sass, Alexander V ^a   Monastyrskaya, Galina S ^a   Kopantzev, Eugene P ^a   Vinogradova, Tatyana V ^a   Khramtsov, Yuri V ^c   Ulasov, Alexey V ^c   Rosenkranz, Andrey A ^c,d   Sobolev, Alexander S ^c,d   Bezborodova, Olga A ^e   Plyutinskaya, Anna D ^e   Nemtsova, Elena R ^e   Yakubovskaya, Raisa I ^e   Sverdlov, Eugene D ^a,b  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

^c INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e P A Herzen Research Oncological Institute   (Russian Federation)

Author keywords

Cancer suicide gene therapy; CMV promoter; GM CSF; HSVtk; Internal ribosome entry site; Metastases; Nonviral vectors; PEG PEI cationic copolymer; Preclinical trials; Targeted therapy

Indexed keywords

GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROGOL; POLYETHYLENEIMINE; POLYETHYLENEIMINE POLYETHYLENE GLYCOL COPOLYMER; SITIMAGENE CERADENOVEC; UNCLASSIFIED DRUG; CATION; INTERNAL RIBOSOME ENTRY SITE; LIPID; LIPOFECTAMINE; MACROGOL DERIVATIVE; POLYMER; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GM CSF GENE; HSVTK GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEWIS CARCINOMA; LIFE EXTENSION; METASTASIS INHIBITION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; SARCOMA; SURVIVAL TIME; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; INTERNAL RIBOSOME ENTRY SITE; LYMPH NODE; METASTASIS; NEOPLASMS; PATHOLOGY; PROCEDURES; SIMPLEXVIRUS; THERAPEUTIC USE; TUMOR CELL LINE;

ANIMALS; CATIONS; CELL LINE, TUMOR; CELL PROLIFERATION; GANCICLOVIR; GENETIC THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERNAL RIBOSOME ENTRY SITES; LIPIDS; LYMPH NODES; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; POLYMERS; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 84928751679     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0433-0     Document Type: Article

References (107)

1. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now? Cancer Lett. 2012;324:160-70.
2. Sverdlov ED. Genetic surgery - a right strategy to attack cancer. Curr Gene Ther. 2011;11:501-31.
3. Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev. 2011;32:1078-91.
4. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release. 2012;164:108-14.
5. Ranganathan R, Madanmohan S, Kesavan A, Baskar G, Krishnamoorthy YR, Santosham R, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine. 2012;7:1043-60.
6. Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, et al. A review on various targeted anticancer therapies. Target Oncol. 2012;7:69-85.
7. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8:66-78.
8. Loisel-Meyer S, Foley R, Medin JA. Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci. 2008;13:3202-14.
9. Podhajcer OL, Lopez MV, Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev. 2007;18:183-94.
10. Brenner MK, Okur FV. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009;2009:675-81.
11. Dougan M, DranoffG. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
12. Vachani A, Moon E, Wakeam E, Haas AR, Sterman DH, Albelda SM. Gene therapy for lung neoplasms. Clin Chest Med. 2011;32:865-85.
13. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1:130-41.
14. Ardiani A, Johnson AJ, Ruan H, Sanchez-Bonilla M, Serve K, Black ME. Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy. Curr Gene Ther. 2012;12:77-91.
15. Xu J, Jin C, Hao S, Luo G, Fu D. Pancreatic cancer: gene therapy approaches and gene delivery systems. Expert Opin Biol Ther. 2010;10:73-88.
16. Hattori Y. Development of nonviral vector for cancer gene therapy. Yakugaku Zasshi. 2010;130:917-23.
17. Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q, et al. Suicide gene therapy for cancer - current strategies. J Genet Syndr Gene Ther. 2013;4:16849.
18. Malecki M. Frontiers in suicide gene therapy of cancer. J Genet Syndr Gene Ther. 2012;3:e114.
19. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med. 2007;28:4-41.
20. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review Curr Gene Ther. 2002;2:307-22.
21. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000;60:3989-99.
22. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules. 2009;14:4517-45.
23. Khatri A, Zhang B, Doherty E, Chapman J, Ow K, Pwint H, et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med. 2006;8:1086-96.
24. Preuss E, Muik A, Weber K, Otte J, von Laer D, Fehse B. Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. J Mol Med (Berl). 2011;89:1113-24.
25. Slavcev R, Wettig S, Kaur T. Nanomedicine based approaches to cancer diagonsis and therapy, nonviral gene therapy. In: Yuan X, editor. Nonviral gene therapy. Rijeka, Croatia: InTech Open Access Publisher; 2011. p. 515-46.
26. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010;70:4297-309.
27. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol. 2005;30:71-88.
28. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33 Suppl 1:S79-84.
29. Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res. 2012;72:6338-43.
30. Berzofsky JA, Terabe M, Wood LV. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol. 2012;39:348-57.
31. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm. 2011;8:12-28.
32. Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, et al. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther. 2013;24:644-54.
33. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188:2391-7.
34. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763-71.
35. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12:6737-47.
36. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med. 2010;10:52-60.
37. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial watch: immunostimulatory cytokines. Oncoimmunology. 2012;1:493-506.
38. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, Yun CO. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther. 2011;19:1558-68.
39. Brockstedt DG, Diagana M, Zhang Y, Tran K, Belmar N, Meier M, et al. Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol Ther. 2002;6:627-36.
40. Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M, et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 2000;7:1086-99.
41. Jones RK, Pope IM, Kinsella AR, Watson AJ, Christmas SE. Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 2000;7:1519-28.
42. Lee KH, Piao H, Son BR, Heo DS, Kim NK, Kim ST. Herpes simplex virus thymidine kinase and granulocyte macrophage colony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model. Cancer Gene Ther. 2004;11:570-6.
43. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between Myeloid-Derived Suppressor Cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012;22:275-81.
44. Lu T, Gabrilovich DI. Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res. 2012;18:4877-82.
45. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol. 2011;77:12-9.
46. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21:822-35.
47. Gutschalk CM, Yanamandra AK, Linde N, Meides A, Depner S, Mueller MM. GM-CSF enhances tumor invasion by elevated MMP-2, -9, and -26 expression. Cancer Med. 2013;2:117-29.
48. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012;21:836-47.
49. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012;20:749-58.
50. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006;14:361-70.
51. Lei N, Shen FB, Chang JH, Wang L, Li H, Yang C, et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther. 2009;16:33-43.
52. Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 2009;2:73-9.
53. Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, et al. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery. 2007;141:520-9.
54. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013;19:2734-44.
55. Prestwich RJ, Errington F, Harrington KJ, Pandha HS, Selby P, Melcher A. Oncolytic viruses: do they have a role in anti-cancer therapy? Clinical Medicine oncology. 2008;2008:83-96.
56. Yue Y, Wu C. Progress and perspectives in developing polymeric vectors for in vitro gene delivery. Biomaterials Science. 2013;1:152-70.
57. Ulasov AV, Khramtsov YV, Trusov GA, Rosenkranz AA, Sverdlov ED, Sobolev AS. Properties of PEI-based polyplex nanoparticles that correlate with their transfection efficacy. Mol Ther. 2011;19:103-12.
58. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED. Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc). 2008;73:1183-91.
59. Alekseenko IV, Kopantzev EP, Vinogradova TV, Sverdlov ED. Bicistronic vector for combined expression of the HSVtk killer gene and cytokine GM-CSF gene in cancer cells. Dokl Biochem Biophys. 2011;439:174-7.
60. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol. 1989;140:323-34.
61. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-702.
62. Mironov A, Bunatian N, Vasyliev A, Varstakova O, Zhuravleva M, Lepahin V, et al. Guidelines for conducting preclinical tests of pharmaceuticals. Moscow, Russia; Part One: Grif & Co Publisher; 2012. In Russian.
63. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem. 2003;278:11411-8.
64. Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, et al. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther. 1997;8:2087-102.
65. Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release. 2005;109:299-316.
66. Wang Y, Xu HX, Lu MD, Tang Q. Expression of thymidine kinase mediated by a novel nonviral delivery system under the control of vascular endothelial growth factor receptor 2 promoter selectively kills human umbilical vein endothelial cells. World J Gastroenterol. 2008;14:224-30.
67. Robles AI, Varticovski L. Harnessing genetically engineered mouse models for preclinical testing. Chem Biol Interact. 2008;171:159-64.
68. Singh M, Murriel CL, Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 2012;72:2695-700.
69. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs. 2005;16:349-59.
70. Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston GJ, et al. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther. 1996;3:83-8.
71. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13-26.
72. Kwiatkowska A, Nandhu MS, Behera P, Chiocca EA, Viapiano MS. Strategies in gene therapy for glioblastoma. Cancers (Basel). 2013;5:1271-305.
73. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med. 2013;15:65-77.
74. Rangarajan A, Weinberg RA. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer. 2003;3:952-9.
75. Greek R, Menache A. Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci. 2013;10:206-21.
76. Greek R, Hansen LA. Questions regarding the predictive value of one evolved complex adaptive system for a second: exemplified by the SOD1 mouse. Prog Biophys Mol Biol. 2013;113:231-53.
77. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175-87.
78. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71-9.
79. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136-51.
80. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412-7.
81. Durymanov MO, Slastnikova TA, Kuzmich AI, Khramtsov YV, Ulasov AV, Rosenkranz AA, et al. Microdistribution of MC1R-targeted polyplexes in murine melanoma tumor tissue. Biomaterials. 2013;34:10209-16.
82. Zhang T, Hamada K, Hyodo M, Itoh H, Tani K, Goda H, et al. Gene therapy for oral squamous cell carcinoma with IAI.3B promoter-driven oncolytic adenovirus-infected carrier cells. Oncol Rep. 2011;25:795-802.
83. Vanneman M, DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237-51.
84. Wei F, Wang H, Zhang J, Chen X, Li C, Huang Q. Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. J Exp Clin Cancer Res. 2013;32:5.
85. Gene therapy. Clinical trials worldwide. J Gene Med. 2014 [http://www.wiley.com//legacy/wileychi/genmed/clinical]
86. Zhou Y, Kopecek J. Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target. 2013;21:1-26.
87. Rosel D, Brabek J, Vesely P, Fernandes M. Drugs for solid cancer: the productivity crisis prompts a rethink. Onco Targets Ther. 2013;6:767-77.
88. Tuting T. T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. Pigment Cell Melanoma Res. 2012;26:441-56.
89. Thorne SH. The role of GM-CSF in enhancing immunotherapy of cancer. Immunotherapy. 2013;5:817-9.
90. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer. 2012;130:1937-47.
91. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res. 2003;20:1337-50.
92. Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, van der Valk P, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5:1703-7.
93. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441-54.
94. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002;8:878-84.
95. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res. 2007;13:2804-10.
96. Hambley TW, Hait WN. Is anticancer drug development heading in the right direction? Cancer Res. 2009;69:1259-62.
97. Flotte TR. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol. 2007;213:301-5.
98. Ohlfest JR, Freese AB, Largaespada DA. Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. Curr Gene Ther. 2005;5:629-41.
99. Templeton NS. Nonviral delivery for genomic therapy of cancer. World J Surg. 2009;33:685-97.
100. Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther. 2012;20:1298-304.
101. Lee WY, Zhang T, Lau CP, Wang CC, Chan KM, Li G. Immortalized human fetal bone marrow-derived mesenchymal stromal cell expressing suicide gene for anti-tumor therapy in vitro and in vivo. Cytotherapy. 2013;15:1484-97.
102. Altaner C. Prodrug cancer gene therapy. Cancer Lett. 2008;270:191-201.
103. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther. 2005;4:512-7.
104. Halama A, Kulinski M, Librowski T, Lochynski S. Polymer-based nonviral gene delivery as a concept for the treatment of cancer. Pharmacol Rep. 2009;61:993-9.
105. Lam P, Khan G, Stripecke R, Hui KM, Kasahara N, Peng KW, et al. The innovative evolution of cancer gene and cellular therapies. Cancer Gene Ther. 2013;20:141-9.
106. Louise C. Nonviral vectors. Methods Mol Biol. 2006;333:201-26.
107. Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, Medina-Franco JL, Gonzalez-Fierro A, Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer. 2008;7:82.